Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in adults with coeliac disease after bolus exposure to gluten (RESET CeD): an interim analysis of a terminated randomised, double-blind, placebo-controlled phase 2 study

Jason A. Tye–Din, A. James M. Daveson, Gautam Goel, Kaela E. Goldstein, Holly L. Hand, Kristin D. Neff, Alina Popp, Juha Taavela, Markku Mäki, Jorma Isola, Leslie Williams, Kenneth E. Truitt, Robert P. Anderson, Atoya Adams, Jane M. Andrews, C. Behrend, Gregor J. Brown, Swee Lin Chen Yi Mei, Allan Coates, Anthony J. DiMarino, Hooi C. Ee, David E. Elliott, ROGER M. EPSTEIN, Bryan John Feyen, Ronald P Fogel, Keith Friedenberg, Richard B. Gearry, Michael S Gerdis, Michael J. Goldstein, Vipin Gupta, Robert Holmes, Gerald J Holtmann, Samuel H Idarraga, G. James, Tim King, Terry D Klein, Sonia S. Kupfer, Benjamin Lebwohl, Matthew John Lowe, Joseph A. Murray, Eric Newton, Dean Quinn, David M Radin, Timothy E. Ritter, Helen Lee Stacey, Cynthia Strout, Richard S. Stubbs, Susan Lynn Thackwray, Vivek M Trivedi, John R Weber, Scott Wilson